Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV trial of Mycobacterium vaccae injection for latent tuberculosis infection in people aged 15 years and older
ChiCTR2300067519Phase 4Not yet recruiting
- Sponsor
- Guangxi Center for Disease Control and Prevention
- Start
- Feb 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycobacterium vaccae in latent tuberculosis infection (LTBI) (2 arms), sponsored by Guangxi Center for Disease Control and Prevention. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
mycobacterium vaccae
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ChiCTR2300067519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067519.